# Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

> **NCT00744016** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 305 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Granulated mesalamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00744016
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-05
- **Final completion:** 2007-10
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744016, "Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00744016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*